Retrospective Study of Immunoembolization for Liver-Dominant Metastatic Uveal Melanoma at a Single Institution - Takeaways - MDSpire

Retrospective Study of Immunoembolization for Liver-Dominant Metastatic Uveal Melanoma at a Single Institution

  • By

  • Renee Morecroft

  • Jordan Phillipps

  • Amrat Kumar

  • Jacob Strelnikov

  • George Nassief

  • Naganathan Mani

  • Jennifer Gould

  • Tanner Johanns

  • George Ansstas

  • April 23, 2026

  • 0 min

Share

  • 1

    Immunoembolization (IE) is a liver-directed therapy for liver-dominant metastatic uveal melanoma (mUM) with limited comparative data.

  • 2

    In a study of 43 patients, the overall disease control rate (DCR) for IE was 27.9%, with a median overall survival (OS) of 32.7 months.

  • 3

    Patients with prior systemic therapy showed improved outcomes, with longer median progression-free survival (PFS) compared to treatment-naïve patients.

  • 4

    IE demonstrated shorter median PFS and lower DCR compared to the FOCUS trial's melphalan/HDS, but longer median OS.

  • 5

    The findings support IE as a viable treatment for liver-dominant mUM, warranting further prospective, multicenter trials for optimal strategies.

Original Source(s)

Retrospective Study of Immunoembolization for Liver-Dominant Metastatic Uveal Melanoma at a Single Institution

  • by Renee Morecroft, Jordan Phillipps, Amrat Kumar, Jacob Strelnikov, George Nassief, Naganathan Mani, Jennifer Gould, Tanner Johanns, George Ansstas

  • April 23, 2026

Related Content

FOXA2 in cancer: from fundamental biology to clinical translation

The role of NAD+ metabolic reprogramming in colorectal cancer chemoresistance: mechanistic insights, clinical translation challenges and opportunities

PD-1 inhibitor combined with chemoradiotherapy in two cases of ovarian cancer brain metastases: a case report